drugset / Trial / NCT04729621
A Study to Test if TVB-009P is Effective in Relieving Postmenopausal Osteoporosis
Phase 3
Completed
332 enrolled
Teva Pharmaceuticals USA
Teva Branded Pharmaceutical Products R&D, Inc. · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of this study is to demonstrate similar efficacy and safety between TVB-009 and Prolia® (denosumab)
Timeline
- Start
- 2021-03-22
- Primary completion
- 2022-12-31
- Completion
- 2023-06-19
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Denosumab | Monoclonal antibody | 60 mg | Subcutaneous |